线粒体积累和 lysosomal 功能障碍导致线粒体斑块在阿尔茨海默氏症的疾病
bioRxiv : the preprint server for biology
|March 3, 2025
概括
研究人员在阿尔茨海默病 (AD) 大脑中发现了线粒体斑块 (MP). 这些MPs含有累积的线粒体,代表了AD的新病理特征和潜在的治疗标.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 功能失调的线粒与阿尔茨海默病 (AD) 病理学有关.
- 直接的体内证据和对阿尔茨海默病中线粒功能障碍的机制性见解是有限的.
研究的目的:
- 通过使用小鼠模型,研究 mitoophagy 在AD 病变发生中的作用.
- 识别和描述与AD相关的新型病理实体.
主要方法:
- 在体内研究中使用了线粒记者小鼠模型 (APP/PSEN1/mt-Keima).
- 检查了AD和对照小鼠的脑组织,以及人类AD和健康的对照大脑.
- 研究了线粒体积累,线粒体和 lysosomal 功能.
主要成果:
- 确定了由AD小鼠和人类大脑中积累的线粒体组成的"线粒体斑块" (MPs),在对照组中不存在.
- 由于缺陷的线粒细胞衰变和 lysosomal 功能受损,观察到异常的线粒体积累在消耗性神经炎中.
- 发现MPs与粉样质斑块共同发展,形成混合斑块.
结论:
- 建立了线粒体斑块 (MPs) 作为阿尔茨海默氏病的新病理实体.
- 证明MPs是由被破坏的线粒体降解和积累引起的.
- 突出了MPs作为AD干预的有希望的治疗点.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
Translocation of Proteins into the Mitochondria
3.0K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
3.0K
Parkinson's Disease: Overview
419
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
419


